Ricevi le ultime notizie sulle azioni Minerva Neurosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NERV

Ultime notizie per

MINERVA NEUROSCIENCES INC

Minerva Neurosciences

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences Inc

NERVGEN PHARMA CORP by NervGen Pharma Corp.

NervGen Pharma Corp

NerveNetwork

Nervos Network

WIIM

NERV-Aktien haben ihre früheren Gewinne aufgegeben. Die Aktien von Minerva Neurosciences wurden höher gehandelt, nachdem das Unternehmen einen Q2 EPS-Schlag gemeldet hatte.

Il titolo NERV ha restituito il guadagno precedente. Le azioni di Minerva Neurosciences stavano scambiando al rialzo dopo che l'azienda ha riportato una superiore EPS nel secondo trimestre.

L'action de NERV a cédé son avance précédente. Les actions de Minerva Neurosciences ont augmenté suite à la publication d'un bénéfice par action supérieur aux attentes pour le T2.

NERV股票已经放弃了之前的涨幅。Minerva Neurosciences股票在公司报告第二季度每股收益超过预期后交易上涨。

NERV 주식은 이전의 이익을 포기했습니다. 미네르바 뉴로과학 주식은 회사가 Q2 EPS를 초과하고 나서 상승했습니다.

Las acciones de NERV han cedido sus ganancias anteriores. Las acciones de Minerva Neurosciences estaban operando al alza después de que la empresa reportara una superación de las ganancias por acción del segundo trimestre.

NERV株は以前の上昇を取り消しました。ミネルバ・ニューロサイエンスの株は、同社が第2四半期のEPSで市場予想を上回ったことを報告した後に取引が上昇していました。

تراجع سهم شركة NERV عن المكاسب السابقة. ارتفعت أسهم Minerva Neurosciences بعد أن أعلنت الشركة عن تجاوز أرباح الربع الثاني للسهم المتوقع.

Minerva Neurosciences Reports Q2 2025 Financial Results

NERV

Abpro Hldgs

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Ainos

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Edesa Biotech

Evaxion

Geovax Labs

iBio

Imunon

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Comments

Minerva Neurosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO